Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...

Both drugs are JAK 1/2 inhibitors and have been cleared for use in adults with severe hair loss caused by the condition. Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming ...

Of the states that do provide coverage for JAK inhibitors used to treat patients with alopecia, researchers found that prior ...

Sun Pharmaceutical has agreed to acquire Checkpoint Therapeutics for an aggregate consideration of up to $355m upfront.

HSBC lowered its target price for Sun Pharmaceuticals to ₹2,000, maintaining a ’buy’ rating. The revision reflects clinical ...

The acquisition is set to add Checkpoint's US Food and Drug Administration (FDA)-approved ... Sun Pharma received FDA approval in July l2024 for Leqselvi (deuruxolitinib), an oral treatment ...

These include slower-than-expected sales pick-up for key specialty brands, further delays in the launch of Leqselvi ... inhibitor drugs, which compete with Sun’s Ilumya brand, reported strong ...

In 2024, India exported drugs worth around $8.73 billion to the ... strong Q3 performance topped expectations, but concerns over Leqselvi’s delayed launch and reduced R&D spending have prompted ...

Both drugs are already approved in the US ... sought by Incyte on the launch of Sun Pharma's recently approved Leqselvi for alopecia areata.

Over the past year, 18 locally based companies secured 21 novel U.S. Food and Drug Administration approvals ... Therapeutics (Kebilidi); Sun Pharma (Leqselvi). During BioNJ’s 32nd annual ...